Asia-Pacific central precocious puberty (CPP) market is projected to register a CAGR of 7.4% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027

Market Segmentation:
Asia-Pacific Central Precocious Puberty (CPP) Treatment market, By Type (Medication, Surgery), Month (1-Month, 3-Month, 6-Month, Others), Route of Administration (Parenteral, Oral, Implants, Others), Gender (Girls, Boys), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (Japan, China, South Korea, Australia, India, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of Asia-Pacific central precocious puberty (CPP) treatment market are:

• Increasing cases of granulosa cell tumors
• Increasing global healthcare expenditure

Market Players:

The key market players for Asia-Pacific central precocious puberty (CPP) market are listed below:

• Ipsen Pharma
• AbbVie Inc.
• Mylan N.V.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi
• DAEWOONG PHARMACEUTICAL CO.,LTD
• AstraZeneca
• Sun Pharmaceutical Industries Ltd
• Endo International plc